Clinical Policy Title: Enhanced cystoscopy for bladder cancer
|
|
- Sibyl McBride
- 5 years ago
- Views:
Transcription
1 Clinical Policy Title: Enhanced cystoscopy for bladder cancer Clinical Policy Number: Effective Date: April Initial Review Date: February Most Recent Review Date: March 6, 2018 Next Review Date: March 2019 Policy contains: Non-muscle invasive bladder cancer. Blue light or fluorescent cystoscopy. Photodynamic diagnosis. Hexaminolevulinate. Related policies: None. ABOUT THIS POLICY: Select Health of South Carolina has developed clinical policies to assist with making coverage determinations. Select Health of South Carolina s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peerreviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Select Health of South Carolina when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Select Health of South Carolina s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Select Health of South Carolina s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Select Health of South Carolina will update its clinical policies as necessary. Select Health of South Carolina s clinical policies are not guarantees of payment. Coverage policy Select Health of South Carolina consider the use of photodynamic diagnosis to be clinically proven and, therefore, medically necessary for the cystoscopic detection of non-muscle invasive bladder cancer when the following criteria are met (National Comprehensive Cancer Network [NCCN], 2018; Chang, 2016; National Institute for Health and Clinical Excellence [NICE], 2015; European Association of Urology [EAU], 2017; U.S. Food and Drug Administration [FDA], 2010b): Performed after or concurrent with white light cystoscopy. Photodynamic diagnosis uses the fluorescence agent hexaminolevulinate, marketed in the United States as Cysview (Cato Research Ltd., Durham, North Carolina) in combination with the Karl Storz D-Light C Photodynamic Diagnostic system (Karl Storz Endoscopy-America Inc., El Segundo, California). For the following clinical indications: At the time of the first three-month cystoscopy in all patients with a history of intermediate- to high-risk non-muscle invasive bladder cancer. 1
2 Exception: patients with low-risk single small non-recurrent low-grade papillary cancers (stage ta), as the expected three-month recurrence rate is less than 15 percent. To guide transurethral resection. Limitations: Contraindications to hexaminolevulinate include porphyria, gross hematuria, intravesical immunotherapy, or chemotherapy within 90 days, or known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives (FDA, 2010b). Repetitive administrations of hexaminolevulinate are not medically necessary (FDA, 2010b). Photodynamic diagnosis using 5-aminolevulinic acid is considered an off-label use and not medically necessary. Alternative covered services: Cytology with urinalysis. White light cystoscopy. Upper urinary tract imaging. Random bladder biopsies. Background Bladder cancer accounts for approximately 5 percent of all new cancers in the United States. It is the fourth most common cancer in men, but it is less common in women (American Cancer Society, 2017). The natural history of bladder cancer ranges from a low-grade variant to high-grade disease (Zlatev, 2015). About half of all bladder cancers are found while the cancer is non-invasive or in situ and still confined to the inner layer of the urothelium. About one in three bladder cancers have invaded into deeper layers but are still only in the bladder. High recurrence rates are associated with bladder cancer, often requiring repeat treatment and lifelong surveillance (Zlatev, 2015). The American Joint Committee on Cancer Tumor, Node, Metastasis (TNM) staging system is used to classify the location and extent of bladder cancer (2017; Table 1): Table 1. TNM staging system for bladder cancer TX: Main tumor cannot be assessed due to lack of information. T0: No evidence of a primary tumor. Ta: Non-invasive papillary carcinoma. Tis: Non-invasive flat carcinoma (flat carcinoma in situ, or carcinoma in situ). 2
3 T1: The tumor has grown from the layer of cells lining the bladder into the connective tissue below. It has not grown into the muscle layer of the bladder. T2: The tumor has grown into the muscle layer: T2a: The tumor has grown only into the inner half of the muscle layer. T2b: The tumor has grown into the outer half of the muscle layer. T3: The tumor has grown through the muscle layer of the bladder and into the fatty tissue layer that surrounds it. T3a: The spread to fatty tissue can only be seen by using a microscope. T3b: The spread to fatty tissue is large enough to be seen on imaging tests or to be seen or felt by the surgeon. T4: The tumor has spread beyond the fatty tissue and into nearby organs or structures. It may be growing into any of the following: the stroma (main tissue) of the prostate, the seminal vesicles, uterus, vagina, pelvic wall, or abdominal wall. T4a: The tumor has spread to the stroma of the prostate (in men), or to the uterus and/or vagina (in women). T4b: The tumor has spread to the pelvic wall or the abdominal wall. For therapeutic purposes, tumors confined to the mucosa and can be treated by transurethral resection and/or intravesical instillations are often referred to as non-muscle invasive bladder cancer. These include papillary tumors confined to the mucosa and invading the lamina propria (stage Ta and T1, respectively) and flat, high-grade tumors that are confined to the mucosa (Tis). However, Tis and T1 lesions can demonstrate a high malignant potential (EAU, 2015, updated 2017). The most common tests used to detect bladder cancer are cytology with urinalysis and transurethral intravesical illumination using white light cystoscopy with biopsy. Cytology detects morphological changes in intact, exfoliated cells. It can identify high-risk disease reliably but tends to miss low-grade or early-stage tumors. White light cystoscopy is unreliable for determining low- and high-grade cancer, assessing level of invasion, differentiating non-papillary and flat malignant lesions (e.g., carcinoma in situ) from inflammation, detecting smaller or satellite tumors, and visualizing submucosal tumor margins during transurethral resection. These limitations can lead to incomplete tumor resection and under-staging, which can increase the risk of cancer persistence, recurrence, and progression (of highgrade cancer) to more lethal disease (Zlatev, 2015; Lopez, 2014). Photodynamic diagnosis in urology: Photodynamic diagnosis in urology (also called blue light cystoscopy or fluorescent cystoscopy) applies the principle of fluorescence under ultraviolet light to distinguish suspicious lesions from non-cancerous mucosa. Innovations in transurethral intravesical illumination using fluorescent markers, which show selective absorption by malignant cells, provide additional contrast enhancement. The goal of these modifications is to improve optical diagnosis beyond standard white light cystoscopy, resulting in more effective use of both bladder sparing management for low-grade cancer and more aggressive treatment for high-grade cancer (Zlatev, 2015; Lopez, 2014). 3
4 Clinical application of photodynamic diagnosis in bladder cancer involves two agents: the heme precursor 5-aminolevulinic acid and its derivative hexaminolevulinate. The U.S. Food and Drug Administration (FDA) has approved 5-aminolevulinic acid for topical use in dermatology; intravesical evaluation of the bladder is an off-label use (FDA, 1999). Hexaminolevulinate is available in the United States as Cysview performed in combination with the Karl Storz D-Light C Photodynamic Diagnostic system for the cystoscopic detection of non-muscle invasive bladder cancer in patients suspected or known to have lesion(s) on the basis of a prior white light cystoscopy (FDA, 2010a and b). Cysview/blue light cystoscopy may be used during an endoscopic examination of the bladder and during resection of bladder cancer. FDA approval highlights the importance of performing a thorough white light examination first, as some lesions may be missed with Cysview/blue light. Cysview is available for single use as a kit with 100-mg hexaminolevulinate powder and a 50-mL solvent, which is instilled in the bladder; the safety of repetitive Cysview administrations has not been assessed. Currently, hexaminolevulinate is not approved for patients who received intravesical immunotherapy or chemotherapy within 90 days, as false-positive results may occur from inflammatory lesions, previous biopsy sites, or in patients previously treated with bacillus Calmette-Guérin (FDA, 2010b). Searches Select Health of South Carolina searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services (CMS). We conducted searches on January 15, Search terms were: Urologic Diseases (MeSH), Urologic Neoplasms (MeSH), Urinary Tract Infections (MeSH), Urinary Tract (MeSH), and Cystoscopy (MeSH). We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings 4
5 We found five systematic reviews/meta-analyses, three evidence-based guidelines, and no costeffectiveness analyses for this policy. Moderate quality evidence from randomized controlled trials (RCTs), nonrandomized controlled trials, and cross-sectional studies comprised the majority of the evidence in the secondary analyses (Gakis, 2016; Chou, 2015; Di Stasi, 2015; Lee, 2015; Burger, 2013). Studies enrolled persons with known or suspected bladder cancer. They compared photodynamic diagnosis using hexaminolevulinate and, to a lesser extent, 5-aminolevulinic acid as an adjunct to white light cystoscopy during initial diagnosis and transurethral resection. The role of photodynamic diagnosis as a replacement for white light cystoscopy has not been evaluated. Most studies reported data by lesion, which may hyperinflate estimates of diagnostic accuracy, as opposed to analysis by patient (i.e., intention-to-treat analyses) that is generally more relevant to assess clinical effectiveness. Cystoscopies were performed in a hospital inpatient setting. Since applying photodynamic diagnosis with 5-aminolevulinic acid during cystoscopy is considered an off label use, this policy will restrict discussion to photodynamic diagnosis using hexaminolevulinate. Photodynamic diagnosis is a reasonably safe procedure, as no serious side effects were noted. The harms associated with any cystoscopy procedure are discomfort, subsequent dysuria and bleeding, and the possibility of urinary tract infection or acute retention. Hexaminolevulinate is contraindicated in patients with porphyria, gross hematuria, intravesical immunotherapy or chemotherapy within 90 days, or known hypersensitivity to hexaminolevulinate or aminolevulinate derivatives. Although repetitive use of hexaminolevulinate has not been evaluated in prospective clinical trials, there are reports that some clinicians may begin repetitive, off-label use of hexaminolevulinate at 6- or 12- month intervals after initial detection of bladder cancer due to fear of missing recurrences that are difficult or impossible to detect with white light cystoscopy (Hayes, 2016 ). One retrospective study with 180 patients and another study that summarized data from six controlled trials (4,324 total patients) and a European registry found no statistically significant differences in the frequency or grade of adverse events between single- and repeat-use of blue light cystoscopy with hexaminolevulinate (Lane, 2017; Witjes, 2014). A registry study that will address the safety and efficacy of repetitive use of hexaminolevulinate in urologists' practices in the United States is underway (ClinicalTrials.gov identifier: NCT ). There is consistent evidence that a single application of photodynamic diagnosis added to white light cystoscopy improves the detection and resection of non-muscle invasive bladder cancer. Photodynamic diagnosis detects significantly more Ta, T1, and carcinoma in situ tumors than white light cystoscopy alone. This benefit extends to most subgroups, including more aggressive, higher risk primary and recurrent bladder cancer. However, the benefits must be weighed against the higher false positive rate (corresponding to lower specificity) of photodynamic diagnosis plus white light cystoscopy, which may result in an increase in unnecessary biopsies. 5
6 The added value of enhanced detection with respect to the risk of recurrence, recurrence-free survival, mortality, progression to muscle-invasive bladder cancer, or cost-effectiveness has not been established. Limited evidence with a high potential for bias suggests photodynamic diagnosis with white light cystoscopy may reduce recurrence rates up to one year, and possibly longer, but the findings were conflicting across studies. Photodynamic diagnosis can miss some high grade lesions found on white light cystoscopy. Use of single-dose adjuvant chemotherapy following transurethral resection of bladder tumor, which alone can reduce recurrence rates, was inconsistently reported or accounted for across studies. Most studies reported a relatively short follow-up period (up to 12 months), which is insufficient to detect changes to invasive cancer, and used various definitions for disease progression. More comparative prospective studies are needed to define the optimum use of photodynamic diagnosis relative to white light cystoscopy. Evidence-based guidelines by the American Urological Association/ Society of Urologic Oncology (AUA/SUO), NICE, and the EAU recommend photodynamic diagnosis-guided transurethral resection for persons with suspected bladder cancer, when available, based on the ability of photodynamic diagnosis to enhance detection and lower recurrence (Chang, 2016; NICE, 2015; EAU, 2015, updated 2017). There is general agreement, based on expert opinion, that photodynamic diagnosis is one of several diagnostic options for patients with a history of non-muscle invasive bladder cancer with normal white light cystoscopy and positive cytology. Other options include prostatic urethral biopsies, upper tract imaging, ureteroscopy, and random bladder biopsies. The EAU further recommends photodynamic diagnosisguided biopsy instead of random biopsies when carcinoma in situ or high-grade tumor is suspected (e.g., positive cytology or recurrent tumor with previous history of a high-grade lesion) based on moderate quality evidence, and either random biopsies or photodynamic diagnosis-guided biopsies after intravesical treatment (at three or six months) in patients with carcinoma in situ based on expert opinion. Policy updates: In 2018, we added two guideline updates on management of bladder cancer: one by the National Comprehensive Cancer Network (2018) and the other by the EAU (2017). Their recommendations for blue light cystoscopy are consistent with the previous findings, and no policy changes are warranted. Summary of clinical evidence: Citation NCCN (2018) Bladder Cancer Guideline EAU (2015, updated 2017) Content, Methods, Recommendations Blue light cystoscopy may be considered in conjunction with white light cystoscopy and clinical expertise to improve staging accuracy. Data are still limited, and white light cystoscopy remains the mainstay of bladder cancer imaging. 6
7 Citation Current guideline: non-muscle invasive bladder cancer Chang (2016) for the AUA/SUO Guideline: diagnosis and treatment of non-muscle invasive bladder cancer Gakis (2016) Impact of white light cystoscopy + hexaminolevulinate vs. white light cystoscopy-guided transurethral resection of bladder tumor in non-muscle invasive bladder cancer on rate of progression Chou (2015) for AHRQ Content, Methods, Recommendations Fluorescence-guided biopsy and resection are more sensitive than conventional procedures for detecting malignant tumors, particularly carcinoma in situ, but less specific. Hexaminolevulinate fluorescence cystoscopy has a beneficial effect on recurrence rate in patients with transurethral resection, but its effect on progression rate, survival, and clinical management is unclear. Use photodynamic diagnosis biopsy instead of random biopsies when bladder carcinoma in situ or high-grade tumor is suspected (e.g., positive cytology, recurrent tumor with previous history of a high-grade lesion). (B: moderate certainty that there are moderate benefits that outweigh the risks/burdens). Use random biopsies or photodynamic diagnosis-guided biopsies after intravesical treatment (at three or six months) in patients with carcinoma in situ. (C) Use random biopsies or photodynamic diagnosis-guided biopsies during follow-up in patients with positive cytology and no visible tumor in the bladder (B). Recommendations based on AHRQ systematic review (Chou, 2015) and expert opinion. Recommend offering blue light cystoscopy at the time of transurethral resection, if available, to increase detection and decrease recurrence (Moderate recommendation; Evidence Strength: Grade B [i.e., moderate certainty that there are moderate benefits that outweigh the risks/burdens]). In a patient with a history of non-muscle invasive bladder cancer with normal cystoscopy and positive cytology, consider prostatic urethral biopsies, upper tract imaging, enhanced cystoscopic techniques (blue light cystoscopy, when available), ureteroscopy, or random bladder biopsies. (Expert Opinion in the absence of evidence). Systematic review and meta-analysis of four RCTs and one retrospective study (1,301 total patients; 644 underwent hexaminolevulinate- and 657 white light-based transurethral resection). Overall quality: moderate with low-to-moderate risk of bias for most randomized studies and low risk of bias for the retrospective study. Limited by variation in definitions of disease progression and length of follow up. Median follow-up (months): white light cystoscopy + hexaminolevulinate 27.6 (range 1 to 55.1) vs. white light cystoscopy alone 28.9 (range 1 to 53). Limited evidence suggests the detection and resection of non-muscle invasive bladder cancer with white light cystoscopy +hexaminolevulinateguided transurethral resection reduces the risk of progression more than white light cystoscopy alone. Emerging approaches to diagnosis and Systematic review and meta-analysis of 13 studies (photodynamic 7
8 Citation treatment of non-muscle invasive bladder cancer: photodynamic diagnosis or narrow band imaging vs. white light cystoscopy Di Stasi (2015) Hexaminolevulinate in the detection of non-muscle invasive bladder cancer Lee (2015) Content, Methods, Recommendations diagnosis only). Overall quality: low-to-moderate with moderate-to-high risk of publication bias and performance bias related to knowledge of the type of initial cystoscopy performed. Photodynamic diagnosis cystoscopy with 5-aminolevulinic acid or hexaminolevulinate vs. white light cystoscopy: No difference in risk of mortality or progression to muscle-invasive bladder cancer. Only one trial was designed to minimize performance bias by blinding the cystoscopist to instillation of the photosensitizer and found no effect. Lower risk of recurrence with photodynamic diagnosis at short-, moderate, and long-term follow up, but findings were inconsistent and susceptible to bias. No clear difference in risk of false positives or renal or genitourinary events (two trials). More research is needed to clarify advantages of photodynamic diagnosis over white light cystoscopy alone. Systematic review of eight prospective RCTs, seven prospective withinpatient comparisons, and one observational comparative controlled trial (3,895 total patients with 2,313 total lesions). Studies were limited by lack of standard data collection methods. White light cystoscopy + hexaminolevulinate photodynamic diagnosis increased overall tumor detection rate vs. white light cystoscopy alone: Detection by lesion Proportion difference type (95% confidence interval [CI]) Ta, T1 and Tis 19% (0.152 to 0.236) Carcinoma in situ 15.7% (0.069 to 0.245) Ta 5.9% (0.014 to 0.103) T1 1.2%, (0.033 to 0.057) Fifteen percent of patients (95% CI to 0.211) had at least one additional tumor seen with photodynamic diagnosis. Insufficient data to assess recurrence rates, but trends favor of hexaminolevulinate-photodynamic diagnosis at three, six and 12 months. Statistically significant difference in the pooled percentage of false positives: White light cystoscopy (SD = 7.06) vs. blue light cystoscopy (SD = 9.24) (p < 0.05). Technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolevulinic acid fluorescence vs. hexaminolevulinate fluorescence vs. narrow band imaging Network meta-analysis of 15 RCTs comparing outcomes of resected nonmuscle invasive bladder cancer using photodynamic diagnosis with 5- aminolevulinic acid, hexaminolevulinate, or narrow band imaging. Overall quality: low with moderate to high risk of bias. Recurrence rates (odds ratio [OR], 95% CI): 5-aminolevulinic acid vs. hexaminolevulinate: (0.48, 0.26 to 0.95). 8
9 Citation NICE (2015) Guidance for bladder cancer diagnosis and management Burger (2013) Content, Methods, Recommendations 5-aminolevulinic acid vs. narrow band imaging (0.53, 0.26 to 1.09). Hexaminolevulinate vs. narrow band imaging (1.11, 0.55 to 2.1). Lower recurrence rates for all photodynamic diagnosis-and NBI-guided resected cancers vs. white light cystoscopy alone. No difference in progression rates for cancers resected by all methods. Recommend offering white-light-guided transurethral resection with one of the following: photodynamic diagnosis, narrow band imaging, cytology, or a urinary biomarker test (such as UroVysion using fluorescence in-situ hybridization, ImmunoCyt or a nuclear matrix protein 22 test) to people with suspected bladder cancer. This should be carried out or supervised by an urologist experienced in transurethral resection. White light cystoscopy vs. white light cystoscopy + hexaminolevulinate-blue light cystoscopy for detection and recurrence of non-muscle invasive bladder tumor Meta-analysis of raw data from nine studies with 1,345 patients with known or suspected non-muscle invasive bladder tumor. Overall quality: moderate to high with low risk of bias. Limited by variable data collection and short follow up of up to 12 months, which is insufficient to detect changes to invasive cancer. Data analysis was by patient (intention-to-treat) and by lesion. Hexaminolevulinate blue light cystoscopy significantly improves the detection of bladder tumors leading to a reduction of recurrence at 9 to 12 mo. The benefit is independent of the level of risk and is evident in patients with Ta, T1, carcinoma in situ, primary, and recurrent cancer. Previous intravesical therapy had no effect on tumor detection, but poorly documented. References Professional society guidelines/other: AJCC Cancer Staging System. American Joint Committee on Cancer website. Accessed January 15, Bladder cancer. American Cancer Society website. Accessed January 15, Bladder cancer: diagnosis and management. NICE Guideline 2. February National Institute for Health and Clinical Excellence website Accessed January 15,
10 Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4): DOI: /j.juro Guidelines on Non-muscle-invasive Bladder Cancer European Association of Urology website. Accessed January 15, NCCN Guidelines Bladder Cancer. Version National Comprehensive Cancer Network website. Accessed January 15, Peer-reviewed references: Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5): DOI: /j.eururo Chou R, Buckley D, Fu R, et al. Emerging Approaches to Diagnosis and Treatment of Non Muscle- Invasive Bladder Cancer. Comparative Effectiveness Review No (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No I.) AHRQ Publication No. 15(16)- EHC017-EF. Rockville, MD: Agency for Healthcare Research and Quality. October Accessed January 15, Di Stasi SM, De Carlo F, Pagliarulo V, et al. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol. 2015; 7(6): DOI: / FDA Approval Letter for NDA Center for Drug Evaluation and Research. FDA website. Accessed January 15, FDA. Karl Storz Endoskope. Photodynamic Diagnostic D-Light C System. Instruction Manual FDA website. Accessed January 15, 2018.(a) FDA. Summary Review for Regulatory Action Orig1s000. Cysview Hexaminolevulinate Hydrochloride for Intravesical Solution FDA website. Accessed January 15, 2018.(b) Gakis G, Fahmy O. Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016; 2(3): DOI: /blc
11 Hayes Inc., Hayes Medical Technology Report. Hexaminolevulinate (Cysview, Hexvix ) for Bladder Cancer Detection. Lansdale, Pa. Hayes Inc.; Updated Lane GI, Downs TM, Soubra A, et al. Tolerability of Repeat Use of Blue Light Cystoscopy with Hexaminolevulinate for Patients with Urothelial Cell Carcinoma. J Urol. 2017; 197(3 Pt 1): DOI: /j.juro Lee JY, Cho KS, Kang DH, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015; 15: 566. DOI: /s Lopez A, Liao JC. Emerging endoscopic imaging technologies for bladder cancer detection. Curr Urol Rep. 2014; 15(5): 406. DOI: /s Witjes JA, Gomella LG, Stenzl A, et al. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. Urology. 2014; 84(1): DOI: /j.urology Zlatev DV, Altobelli E, Liao JC. Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am. 2015; 42(2): , vii. DOI: /j.ucl CMS National Coverage Determinations (NCDs): No NCDs identified as of the writing of this policy. Local Coverage Determinations (LCDs): No LCDs identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comments Cystourethroscopy (separate procedure) Cystourethroscopy, with biopsy(s) Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands 11
12 CPT Code Description Comments Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or without biopsy Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of SMALL bladder tumor(s) (0.5 to 2.0 cm) Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of MEDUIUM bladder tumor(s) (2.0 to 5.0 cm) Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of LARGE bladder tumor(s) ICD-10 Code Description Comments C67.0-C67.9 Neoplasm of bladder HCPCS Level II Code C9275 Description Injection, hexaminolevulinate hydrochloride, 100 mg, per study Comments 12
Clinical Policy Title: Enhanced cystoscopy for bladder cancer
Clinical Policy Title: Enhanced cystoscopy for bladder cancer Clinical Policy Number: 13.01.04 Effective Date: April 1, 2017 Initial Review Date: February 15, 2017 Most Recent Review Date: March 15, 2017
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationMEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR BLADDER CANCER. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: URINARY TUMOR MARKERS FOR PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: February 15, 2017 Report Length: 15 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Blue Light Cystoscopy in Patients with Suspected Non-Muscle Invasive Bladder Carcinoma: A Review of Clinical Utility Service Line: Rapid Response
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationIntroduction. Bladder cancer is the second most common genitourinary malignancy in the United States and the fifth most
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride
More informationCorporate Medical Policy
Corporate Medical Policy Urinary Tumor Markers for Bladder Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: urinary_tumor_markers_for_bladder_cancer 5/2011 11/2017 11/2018
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationThe Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis
Bladder Cancer 2 (2016) 273 278 DOI 10.3233/BLC-160048 IOS Press Research Report 273 The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer ANewAnalysis Ashish
More informationCYSVIEW. CONFIDENCE AT FIRST SIGHT
CYSVIEW. CONFIDENCE AT FIRST SIGHT Blue Light Cystoscopy with CYSVIEW Cysview Indication Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle invasive papillary
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationEffective Health Care Program
Comparative Effectiveness Review Number 153 Effective Health Care Program Emerging Approaches to Diagnosis and Treatment of Non Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer
More informationDiagnosis and classification
Patient Information English 2 Diagnosis and classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour is present.
More informationWhat You Need to Know About Bladder Cancer. Sponsored by:
What You Need to Know About Bladder Cancer Sponsored by: When It's About Your Bladder 1 Your bladder plays an important role in your body by collecting urine from the kidneys, then holding it until you
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationKARL STORZ Blue Light Cystoscopy with Cysview System. Photodynamic Diagnosis (PDD)
KARL STORZ Blue Light Cystoscopy with Cysview System Photodynamic Diagnosis (PDD) Bladder cancer affects over 580,000 patients in the US. It is the #4 cancer in men and is observed in men 3-4 times more
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationThe innovative aspect is that it detects bladder cancer based on the novel biomarker, minichromosome maintenance complex component 5 (MCM5).
pat hways ADXBLADDER for detecting bladder cancer Medtech innovation briefing Published: 12 April 2019 nice.org.uk/guidance/mib180 Summary The technology described in this briefing is ADXBLADDER. It is
More informationClinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering)
Clinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering) Clinical Policy Number: 17.02.02 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationSymptoms, Diagnosis and Classification
Patient Information English 2 Symptoms, Diagnosis and Classification The underlined terms are listed in the glossary. Signs and symptoms Blood in the urine is the most common symptom when a bladder tumour
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationRelated Policies None
Medical Policy MP 2.04.07 BCBSA Ref. Policy: 2.04.07 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 09/27/2018 Related Policies None DISCLAIMER Our medical policies are
More informationDiagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
More informationUrinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance Policy Number: 2.04.07 Last Review: 12/2018 Origination: 12/2016 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationBLADDER CANCER CONTENT CREATED BY. Learn more at
BLADDER CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK TO YOUR DOCTOR Table of Contents WHAT IS BLADDER CANCER? 4 TYPES OF BLADDER CANCER 5 GRADING AND STAGING 8 TREATMENT OVERVIEW
More informationINCREASE DETECTION, REDUCE RECURRENCE. NBI Is Clinically Proven to Diagnose More Bladder Cancer
INCREASE DETECTION, REDUCE RECURRENCE NBI Is Clinically Proven to Diagnose More Bladder Cancer 16241 1 NBI PROVEN FOR BETTER CLINICAL OUTCOMES INCREASE DETECTION, REDUCE RECURRENCE Narrow Band Imaging
More informationBladder Cancer Early Detection, Diagnosis, and Staging
Bladder Cancer Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationProtocol. Urinary Tumor Markers for Bladder Cancer
Protocol Urinary Tumor Markers for Bladder Cancer (20407) Medical Benefit Effective Date: 01/01/13 Next Review Date: 09/18 Preauthorization No Review Dates: 03/12, 09/12, 09/13, 09/14, 09/15, 09/16, 09/17
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationBladder Cancer Canada November 21st, Bladder Cancer 2018: A brighter light at the end of the cystoscope
Bladder Cancer Canada November 21st, 2018 Bladder Cancer 2018: A brighter light at the end of the cystoscope Chris Morash MD FRCSC Associate Professor, University of Ottawa Head, Urological Oncology Bladder
More informationCosting report: Bladder cancer
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationClinical Policy Title: Vacuum assisted closure in surgical wounds
Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Number: 17.03.00 Effective Date: September 1, 2015 Initial Review Date: June 16, 2013 Most Recent Review Date: August 17,
More information13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 5 WARNINGS AND PRECAUTIONS Animal Toxicology and/or Pharmacology 5.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CYSVIEW safely and effectively. See full prescribing information for CYSVIEW. Cysview (hexaminolevulinate
More informationDecember 22, Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN
December 22, 2016 Earl Berman, MD Attn Medical Review Two Vantage Way Nashville, TN 37228 cmd.inquiry@cgsadmin.com Re: Draft Local Coverage Determination - Bladder Tumor Markers (DL36975) Dear Dr. Berman:
More informationClinical Policy Title: Discography
Clinical Policy Title: Discography Clinical Policy Number: 03.01.01 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2017 Next Review Date: October
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationClinical Policy Title: Tactile breast imaging
Clinical Policy Title: Tactile breast imaging Clinical Policy Number: 05.01.07 Effective Date: February 1, 2018 Initial Review Date: November 16, 2017 Most Recent Review Date: January 11, 2018 Next Review
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 11.03.05 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationStone Management Coding & Payment Quick Reference
Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements. The coding options listed within this guide are commonly used codes
More informationIntroduction. Phil Hyun Song, MD, PhD 1 Seok Cho, MD 2 Young Hwii Ko, MD, PhD 1. pissn , eissn
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(1):273-280 Original Article http://dx.doi.org/10.4143/crt.2014.190 Open Access Decision Based on Narrow Band Imaging Cystoscopy without a Referential
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationLet us know how access to this document benefits you
Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 7-2014 Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined
More informationBladder cancer - suspected
Background information Information resources for patients and carers Updates to this care map Bladder cancer - clinical presentation History Examination Consider differential diagnoses Clinical indications
More informationClinical Policy Title: Room humidifiers
Clinical Policy Title: Room humidifiers Clinical Policy Number: 17.02.05 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: November 16, 2016 Next Review Date:
More informationHaematuria and Bladder Cancer
Haematuria and Bladder Cancer Dr Pardeep Kumar Consultant Urological Surgeon Haematuria 3 Haematuria Macroscopic vs Microscopic Painful vs Painless Concurrent abdo pain/urinary symptoms Previous testing?
More informationInformation for Patients. Bladder Cancer. English
Information for Patients Bladder Cancer English Table of contents What is the function of the bladder?... 3 What is bladder cancer?... 3 What causes bladder cancer?... 3 Stages of the disease... 3 Risk
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationOriginal Policy Date
MP 7.01.39 Transurethral Microwave Thermotherapy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationNOW BLUE LIGHT CYSTOSCOPY WITH CYSVIEW CONFIDENCE AT FIRST SIGHT. A Health Care Professional s Guide. approved in surveillance and TURBT
NOW approved in surveillance and TURBT BLUE LIGHT CYSTOSCOPY WITH CYSVIEW CONFIDENCE AT FIRST SIGHT A Health Care Professional s Guide Reconstitution of Cysview BLUE LIGHT CYSTOSCOPY WITH CYSVIEW EQUIPMENT
More informationTOPICS FOR DISCUSSION
INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: June 22, 2017 Next Review Date:
More informationPart II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by
Women & Bladder Cancer A Woman-to-Woman Talk with Dr. Armine Smith Wednesday, March 8, 2017 Part II: Treatment Presented by Dr. Smith is an Assistant Professor of Urology at Johns Hopkins University and
More informationUNDERSTANDING BLUE LIGHT CYSTOSCOPY WITH CYSVIEW FOR DETECTION OF BLADDER CANCER 2
Included in National Urology Guidelines 1 VISIT CYSVIEW.COM UNDERSTANDING BLUE LIGHT CYSTOSCOPY WITH CYSVIEW FOR DETECTION OF BLADDER CANCER 2 A PATIENT GUIDE Cysview can only be used by qualified healthcare
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationConfocal Endomicroscopy in Urologic Surgery: urothelial carcinoma and other emerging applications
INTERNATIONAL SOCIETY FOR ENDOMICROSCOPY (IS4E) PARIS, FRANCE NOVEMBER 27, 2017 Confocal Endomicroscopy in Urologic Surgery: urothelial carcinoma and other emerging applications Joseph C. Liao, MD Department
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCarcinoma of the Renal Pelvis and Ureter Histopathology
Carcinoma of the Renal Pelvis and Ureter Histopathology Reporting Proforma (NEPHROURETERECTOMY AND URETERECTOMY) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationEAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)
EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) M. Babjuk (Chair), M. Burger (Vice-Chair), E. Compérat, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S.F. Shariat,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationEfficient and Effective Use of Exfoliative Markers
Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationOriginal Policy Date
MP 2.04.05 Urinary Tumor Markers for Bladder Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 1135 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: August 1, 2018 Next Review
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationMultiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationAfterword: The Paris System for Reporting Urinary Cytology
Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology
More informationClinical Policy Title: Seasonal influenza testing
Clinical Policy Title: Seasonal influenza testing Clinical Policy Number: 07.01.08 Effective Date: October 1, 2017 Initial Review Date: August 17, 2017 Most Recent Review Date: September 21, 2017 Next
More informationCorporate Medical Policy
Corporate Medical Policy Multigene Expression Assay for Predicting Recurrence in Colon File Name: Origination: Last CAP Review: Next CAP Review: Last Review: multigene_expression_assay_for_predicting_recurrence_in_colon_cancer
More information